Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls

Ilir Agalliu; Roberto A. Ortega; Marta San Luciano; Anat Mirelman; Claustre Pont-Sunyer; Kathrin Brockmann; Dolores Vilas; Eduardo Tolosa; Daniela Berg; Bjørg Warø; Amanda Glickman; Deborah Raymond; Rivka Inzelberg; Javier Ruiz-Martinez; Elisabet Mondragon; Eitan Friedman; Sharon Hassin-Baer; Roy N. Alcalay; Helen Mejia-Santana; Jan Aasly; Tatiana Foroud; Karen Marder; Nir Giladi; Susan Bressman; Rachel Saunders-Pullman

doi:10.1002/mds.27807

Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls

Ilir Agalliu, Roberto A. Ortega, Marta San Luciano, Anat Mirelman, Claustre Pont-Sunyer, Kathrin Brockmann, Dolores Vilas, Eduardo Tolosa, Daniela Berg, Bjørg Warø, Amanda Glickman, Deborah Raymond, Rivka Inzelberg, Javier Ruiz-Martinez, Elisabet Mondragon, Eitan Friedman, Sharon Hassin-Baer, Roy N. Alcalay, Helen Mejia-Santana, Jan AaslyTatiana Foroud, Karen Marder, Nir Giladi, Susan Bressman, Rachel Saunders-Pullman

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Abstract

Background: Increased cancer risk has been reported in Parkinson's disease (PD) patients carrying the leucine rich repeat kinase 2 (LRRK2) G2019S mutation (LRRK2-PD) in comparison with idiopathic PD (IPD). It is unclear whether the elevated risk would be maintained when compared with unaffected controls. Methods: Cancer outcomes were compared among 257 LRRK2-PD patients, 712 IPD patients, and 218 controls recruited from 7 LRRK2 consortium centers using mixed-effects logistic regression. Data were then pooled with a previous study to examine cancer risk between 401 LRRK2-PD and 1946 IPD patients. Results: Although cancer prevalence was similar among LRRK2-PD patients (32.3%), IPD patients (27.5%), and controls (27.5%; P = 0.33), LRRK2-PD had increased risks of leukemia (odds ratio [OR] = 4.55; 95% confidence interval [CI], 1.46–10.61) and skin cancer (OR = 1.61; 95% CI, 1.09–2.37). In the pooled analysis, LRRK2-PD patients had also elevated risks of leukemia (OR = 9.84; 95% CI, 2.15–44.94) and colon cancer (OR = 2.34; 95% CI, 1.15–4.74) when compared with IPD patients. Conclusions: The increased risks of leukemia as well as skin and colon cancers among LRRK2-PD patients suggest that LRRK2 mutations heighten risks of certain cancers.

Original language	English
Pages (from-to)	1392-1398
Number of pages	7
Journal	Movement Disorders
Volume	34
Issue number	9
DOIs	https://doi.org/10.1002/mds.27807
State	Published - 1 Sep 2019
Externally published	Yes

Keywords

G2019S mutation
LRRK2 gene
Parkinson's disease
colon cancer
leukemia
pooled analysis

ASJC Scopus subject areas

Neurology
Clinical Neurology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/mds.27807

Cite this

Agalliu, I., Ortega, R. A., Luciano, M. S., Mirelman, A., Pont-Sunyer, C., Brockmann, K., Vilas, D., Tolosa, E., Berg, D., Warø, B., Glickman, A., Raymond, D., Inzelberg, R., Ruiz-Martinez, J., Mondragon, E., Friedman, E., Hassin-Baer, S., Alcalay, R. N., Mejia-Santana, H., ... Saunders-Pullman, R. (2019). Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls. Movement Disorders, 34(9), 1392-1398. https://doi.org/10.1002/mds.27807

@article{245f0d60ddc144c291baeeb1812caee9,

title = "Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls",

abstract = "Background: Increased cancer risk has been reported in Parkinson's disease (PD) patients carrying the leucine rich repeat kinase 2 (LRRK2) G2019S mutation (LRRK2-PD) in comparison with idiopathic PD (IPD). It is unclear whether the elevated risk would be maintained when compared with unaffected controls. Methods: Cancer outcomes were compared among 257 LRRK2-PD patients, 712 IPD patients, and 218 controls recruited from 7 LRRK2 consortium centers using mixed-effects logistic regression. Data were then pooled with a previous study to examine cancer risk between 401 LRRK2-PD and 1946 IPD patients. Results: Although cancer prevalence was similar among LRRK2-PD patients (32.3%), IPD patients (27.5%), and controls (27.5%; P = 0.33), LRRK2-PD had increased risks of leukemia (odds ratio [OR] = 4.55; 95% confidence interval [CI], 1.46–10.61) and skin cancer (OR = 1.61; 95% CI, 1.09–2.37). In the pooled analysis, LRRK2-PD patients had also elevated risks of leukemia (OR = 9.84; 95% CI, 2.15–44.94) and colon cancer (OR = 2.34; 95% CI, 1.15–4.74) when compared with IPD patients. Conclusions: The increased risks of leukemia as well as skin and colon cancers among LRRK2-PD patients suggest that LRRK2 mutations heighten risks of certain cancers.",

keywords = "G2019S mutation, LRRK2 gene, Parkinson's disease, colon cancer, leukemia, pooled analysis",

author = "Ilir Agalliu and Ortega, {Roberto A.} and Luciano, {Marta San} and Anat Mirelman and Claustre Pont-Sunyer and Kathrin Brockmann and Dolores Vilas and Eduardo Tolosa and Daniela Berg and Bj{\o}rg War{\o} and Amanda Glickman and Deborah Raymond and Rivka Inzelberg and Javier Ruiz-Martinez and Elisabet Mondragon and Eitan Friedman and Sharon Hassin-Baer and Alcalay, {Roy N.} and Helen Mejia-Santana and Jan Aasly and Tatiana Foroud and Karen Marder and Nir Giladi and Susan Bressman and Rachel Saunders-Pullman",

note = "Publisher Copyright: {\textcopyright} 2019 International Parkinson and Movement Disorder Society",

year = "2019",

month = sep,

day = "1",

doi = "10.1002/mds.27807",

language = "English",

volume = "34",

pages = "1392--1398",

journal = "Movement Disorders",

issn = "0885-3185",

publisher = "John Wiley and Sons Inc.",

number = "9",

}

Agalliu, I, Ortega, RA, Luciano, MS, Mirelman, A, Pont-Sunyer, C, Brockmann, K, Vilas, D, Tolosa, E, Berg, D, Warø, B, Glickman, A, Raymond, D, Inzelberg, R, Ruiz-Martinez, J, Mondragon, E, Friedman, E, Hassin-Baer, S, Alcalay, RN, Mejia-Santana, H, Aasly, J, Foroud, T, Marder, K, Giladi, N, Bressman, S & Saunders-Pullman, R 2019, 'Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls', Movement Disorders, vol. 34, no. 9, pp. 1392-1398. https://doi.org/10.1002/mds.27807

TY - JOUR

T1 - Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls

AU - Agalliu, Ilir

AU - Ortega, Roberto A.

AU - Luciano, Marta San

AU - Mirelman, Anat

AU - Pont-Sunyer, Claustre

AU - Brockmann, Kathrin

AU - Vilas, Dolores

AU - Tolosa, Eduardo

AU - Berg, Daniela

AU - Warø, Bjørg

AU - Glickman, Amanda

AU - Raymond, Deborah

AU - Inzelberg, Rivka

AU - Ruiz-Martinez, Javier

AU - Mondragon, Elisabet

AU - Friedman, Eitan

AU - Hassin-Baer, Sharon

AU - Alcalay, Roy N.

AU - Mejia-Santana, Helen

AU - Aasly, Jan

AU - Foroud, Tatiana

AU - Marder, Karen

AU - Giladi, Nir

AU - Bressman, Susan

AU - Saunders-Pullman, Rachel

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Background: Increased cancer risk has been reported in Parkinson's disease (PD) patients carrying the leucine rich repeat kinase 2 (LRRK2) G2019S mutation (LRRK2-PD) in comparison with idiopathic PD (IPD). It is unclear whether the elevated risk would be maintained when compared with unaffected controls. Methods: Cancer outcomes were compared among 257 LRRK2-PD patients, 712 IPD patients, and 218 controls recruited from 7 LRRK2 consortium centers using mixed-effects logistic regression. Data were then pooled with a previous study to examine cancer risk between 401 LRRK2-PD and 1946 IPD patients. Results: Although cancer prevalence was similar among LRRK2-PD patients (32.3%), IPD patients (27.5%), and controls (27.5%; P = 0.33), LRRK2-PD had increased risks of leukemia (odds ratio [OR] = 4.55; 95% confidence interval [CI], 1.46–10.61) and skin cancer (OR = 1.61; 95% CI, 1.09–2.37). In the pooled analysis, LRRK2-PD patients had also elevated risks of leukemia (OR = 9.84; 95% CI, 2.15–44.94) and colon cancer (OR = 2.34; 95% CI, 1.15–4.74) when compared with IPD patients. Conclusions: The increased risks of leukemia as well as skin and colon cancers among LRRK2-PD patients suggest that LRRK2 mutations heighten risks of certain cancers.

AB - Background: Increased cancer risk has been reported in Parkinson's disease (PD) patients carrying the leucine rich repeat kinase 2 (LRRK2) G2019S mutation (LRRK2-PD) in comparison with idiopathic PD (IPD). It is unclear whether the elevated risk would be maintained when compared with unaffected controls. Methods: Cancer outcomes were compared among 257 LRRK2-PD patients, 712 IPD patients, and 218 controls recruited from 7 LRRK2 consortium centers using mixed-effects logistic regression. Data were then pooled with a previous study to examine cancer risk between 401 LRRK2-PD and 1946 IPD patients. Results: Although cancer prevalence was similar among LRRK2-PD patients (32.3%), IPD patients (27.5%), and controls (27.5%; P = 0.33), LRRK2-PD had increased risks of leukemia (odds ratio [OR] = 4.55; 95% confidence interval [CI], 1.46–10.61) and skin cancer (OR = 1.61; 95% CI, 1.09–2.37). In the pooled analysis, LRRK2-PD patients had also elevated risks of leukemia (OR = 9.84; 95% CI, 2.15–44.94) and colon cancer (OR = 2.34; 95% CI, 1.15–4.74) when compared with IPD patients. Conclusions: The increased risks of leukemia as well as skin and colon cancers among LRRK2-PD patients suggest that LRRK2 mutations heighten risks of certain cancers.

KW - G2019S mutation

KW - LRRK2 gene

KW - Parkinson's disease

KW - colon cancer

KW - leukemia

KW - pooled analysis

UR - http://www.scopus.com/inward/record.url?scp=85072546686&partnerID=8YFLogxK

U2 - 10.1002/mds.27807

DO - 10.1002/mds.27807

M3 - Article

AN - SCOPUS:85072546686

SN - 0885-3185

VL - 34

SP - 1392

EP - 1398

JO - Movement Disorders

JF - Movement Disorders

IS - 9

ER -

Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this